Citigroup initiated coverage on ArriVent BioPharma with a new price target
$AVBP
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $37.00 | Buy | B. Riley Securities |
| 3/10/2025 | $45.00 | Buy | Guggenheim |
| 7/22/2024 | $35.00 | Outperform | Oppenheimer |
| 4/30/2024 | $25.00 | Buy | H.C. Wainwright |
| 2/20/2024 | $35.00 | Buy | Jefferies |
| 2/20/2024 | $27.00 | Buy | Goldman |
| 2/20/2024 | $30.00 | Buy | Citigroup |
4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)
SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)
SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr
NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. "We are excited to welcome Dr. Hohneker to our Board of Directors and look forward to his partnership as we work to advance our pipeline, includin
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. "We are thrilled for Kris to join our Board of Directors at such an important time for ArriVent, as we advance the development of firmonertinib in multiple non-small cell lung cancer ("NSCLC") indications," said Bing Yao, Chairman and C
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr
First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollmentSelected next-generation ADC candidate ARR-002 for IND enabling studiesCash and cash equivalents of $266.5 million as of December 31, 2024 NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financia
Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission planned for 1H 2025Expands ArriVent's growing pipeline of next-generation ADCs NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) th
B. Riley Securities initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $37.00
Guggenheim initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00
Oppenheimer initiated coverage of ArriVent BioPharma with a rating of Outperform and set a new price target of $35.00
DEFA14A - ArriVent BioPharma, Inc. (0001868279) (Filer)
DEF 14A - ArriVent BioPharma, Inc. (0001868279) (Filer)
8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)